The Korea Drug Development Fund (KDDF) is the largest public funder of drug research and development (R&D) in Korea. KDDF invests more than $150 million per year in promising projects across almost ...

SEOUL, South Korea, January 05, 2026--(BUSINESS WIRE)--Curogen Technology Co., Ltd. ("Curogen"), a South Korea-based biotechnology company focused on developing innovative treatments for autoimmune ...

The Korea Drug Development Fund (KDDF) is a major force in Korean research and development (R&D). Through the use of its $1 billion, 9-year budget, the government-funded organization has selected more ...

San Diego, CA | Novotech, Australia's largest clinical CRO with offices throughout Asia, has signed an MOU with the Korea Drug Development Fund (KDDF) to promote the development of the Korean ...

Bayer Korea said on the 27th that it signed a memorandum of understanding (MOU) with the Korea Drug Development Fund (KDDF) to expand cooperation in Korea's pharmaceutical and biotech industry and to ...

A supportive government, modern infrastructure and easily accessible patient population are helping this Asian nation become a top location for clinical trial research. South Korea, a country in ...

D&D Pharmatech, a company specializing in developing new drugs in the glucagon-like peptide (GLP)-1 class, said on the 16th that DD01, its investigational new drug candidate for treating metabolic ...

WCCT Global announced today a mutual cooperation and business agreement with Korea Drug Development Fund (KDDF) located in Seoul, South Korea WCCT Global announced today a mutual cooperation and ...

In an initiative to strengthen early phase clinical research in South Korea, Celerion and the Korean Drug Development Fund (KDDF) entered a collaboration providing expertise and support for the ...

ROCKVILLE, Md.--(BUSINESS WIRE)--Genexine, a clinical stage biotechnology company developing innovative biologics, and its spin-off company in the US, NeoImmuneTech, Inc. (NIT), today announced that ...

Curogen Technology Co., Ltd. (”Curogen”), a South Korea-based biotechnology company focused on developing innovative treatments for autoimmune diseases, announced that it received its fifth national ...